title: A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD.
abstract: OBJECTIVE
  The aim of this study was to study treatment response to atomoxetine in a large, multicenter study of non-North American patients with ADHD.
  
  
  METHODS
  A total of 604 children and adolescents with ADHD were enrolled in a 10-week open-label trial with atomoxetine prior to randomization to a double-blind relapse prevention phase at 33 sites in the United Kingdom, continental Europe, Israel, South Africa, and Australia. All patients had ADHD symptom severity at least 1.5 standard deviations above United States age and gender norms for their diagnostic subtype as measured by the investigator-scored ADHD Rating Scale (ADHD RS). Outcomes were assessed by analysis of change in the ADHD RS; functional and psychosocial outcomes were assessed using the Child Health Questionnaire (CHQ).
  
  
  RESULTS
  At endpoint, ADHD RS total scores decreased by an average of 56.7%, and 69% of patients were rated as having no or minimal symptoms. Significant improvement was observed in psychosocial and functional outcomes. Discontinuations attributed to adverse events were < 4%.
  
  
  CONCLUSIONS
  These open-label data, gathered in an international setting, add to our knowledge of the value of atomoxetine in treating ADHD symptoms, as well as its safety and tolerability.
authors.affiliation: Department of Psychiatry, University Medical Center Nijmegen, 9101, 6500, HB Nijmegen, The Netherlands.
authors.forename: Jan K
authors.initials: JK
authors.lastname: Buitelaar
authors.forename: Marina
authors.initials: M
authors.lastname: Danckaerts
authors.forename: Christopher
authors.initials: C
authors.lastname: Gillberg
authors.forename: Alessandro
authors.initials: A
authors.lastname: Zuddas
authors.forename: Katja
authors.initials: K
authors.lastname: Becker
authors.forename: Manuel
authors.initials: M
authors.lastname: Bouvard
authors.forename: Jenny
authors.initials: J
authors.lastname: Fagan
authors.forename: Julia
authors.initials: J
authors.lastname: Gadoros
authors.forename: Valerie
authors.initials: V
authors.lastname: Harpin
authors.forename: Philip
authors.initials: P
authors.lastname: Hazell
authors.forename: Mats
authors.initials: M
authors.lastname: Johnson
authors.forename: Tally
authors.initials: T
authors.lastname: Lerman-Sagie
authors.forename: Cesar A
authors.initials: CA
authors.lastname: Soutullo
authors.forename: Tomasz
authors.initials: T
authors.lastname: Wolanczyk
authors.forename: Pal
authors.initials: P
authors.lastname: Zeiner
authors.forename: Daniel S
authors.initials: DS
authors.lastname: Fouche
authors.forename: Judith
authors.initials: J
authors.lastname: Krikke-Workel
authors.forename: Shuyu
authors.initials: S
authors.lastname: Zhang
authors.forename: David
authors.initials: D
authors.lastname: Michelson
mesh_terms: D000293:Adolescent; D018663:Adrenergic Agents / Q000627:therapeutic use*; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000188:drug therapy* / Q000208:ethnology*; D002648:Child; D039721:Diagnostic and Statistical Manual of Mental Disorders; D005260:Female; D006801:Humans; D008297:Male; D011437:Propylamines / Q000627:therapeutic use*; D011446:Prospective Studies; D012720:Severity of Illness Index
chemical_list: D018663:Adrenergic Agents; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride